Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Schoppmann

Showing results (231-240 of 277) with videos related to

Pageof 28
Sort By:
Cells|December 29, 2020
Erratum: Gruber, E.S.; et al. The Oncogene AF1Q is Associated with WNT and STAT Signaling and Offers a Novel Independent Prognostic Marker in Patients with Resectable Esophageal Cancer. <i>Cells</i> 2019, <i>8</i>, 1357Elisabeth S Gruber, Georg Oberhuber, Peter Birner, et al.
Pathology Oncology Research : POR|May 7, 2020
PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control StudyAndrea Beer, Hossein Taghizadeh, Ana-Iris Schiefer, et al.
Annals of Surgery|July 27, 2004
Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancerSebastian F Schoppmann, Guenther Bayer, Klaus Aumayr, et al.
Anticancer Research|July 31, 2013
Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tractAysegül Ilhan-Mutlu, Matthias Preusser, Sebastian F Schoppmann, et al.
European Radiology|June 29, 2011
Accuracy of hydro-multidetector row CT in the local T staging of oesophageal cancer compared to postoperative histopathological resultsAhmed Ba-Ssalamah, Wolfgang Matzek, Susanne Baroud, et al.
International Journal of Surgery (London, England)|September 4, 2013
Surgical treatment of GIST--an institutional experience of a high-volume centerKatrin Schwameis, Alexandra Fochtmann, Michael Schwameis, et al.
Anticancer Research|March 14, 2013
Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapiesMatthias Preusser, Anna S Berghoff, Aysegül Ilhan-Mutlu, et al.
Clinical Breast Cancer|June 30, 2009
Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?Michael Gnant, Peter Dubsky, Florian Fitzal, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 20, 2014
The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group studyDaniela Kandioler, Sebastian F Schoppmann, Ronald Zwrtek, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 18, 2021
Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatmentGerd Jomrich, Dagmar Kollmann, Dariga Ramazanova, et al.
Pageof 28

Showing results (231-240 of 277) with videos related to

Sort By:
Pageof 28
Cells|December 29, 2020
Erratum: Gruber, E.S.; et al. The Oncogene AF1Q is Associated with WNT and STAT Signaling and Offers a Novel Independent Prognostic Marker in Patients with Resectable Esophageal Cancer. <i>Cells</i> 2019, <i>8</i>, 1357Elisabeth S Gruber, Georg Oberhuber, Peter Birner, et al.
Pathology Oncology Research : POR|May 7, 2020
PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control StudyAndrea Beer, Hossein Taghizadeh, Ana-Iris Schiefer, et al.
Annals of Surgery|July 27, 2004
Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancerSebastian F Schoppmann, Guenther Bayer, Klaus Aumayr, et al.
Anticancer Research|July 31, 2013
Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tractAysegül Ilhan-Mutlu, Matthias Preusser, Sebastian F Schoppmann, et al.
European Radiology|June 29, 2011
Accuracy of hydro-multidetector row CT in the local T staging of oesophageal cancer compared to postoperative histopathological resultsAhmed Ba-Ssalamah, Wolfgang Matzek, Susanne Baroud, et al.
International Journal of Surgery (London, England)|September 4, 2013
Surgical treatment of GIST--an institutional experience of a high-volume centerKatrin Schwameis, Alexandra Fochtmann, Michael Schwameis, et al.
Anticancer Research|March 14, 2013
Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapiesMatthias Preusser, Anna S Berghoff, Aysegül Ilhan-Mutlu, et al.
Clinical Breast Cancer|June 30, 2009
Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?Michael Gnant, Peter Dubsky, Florian Fitzal, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 20, 2014
The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group studyDaniela Kandioler, Sebastian F Schoppmann, Ronald Zwrtek, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 18, 2021
Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatmentGerd Jomrich, Dagmar Kollmann, Dariga Ramazanova, et al.
Pageof 28